Directional coronary atherectomy in acute myocardial infarction.
To date, application of directional coronary atherectomy (DCA) in acute myocardial infarction (AMI) has had limited reports.  In eleven patients with AMI, DCA was applied.  In three of these patients, DCA was used as a stand-alone procedure without use of thrombolytic agents.  In each case a guidewire was placed across the stenosis, and in eight patients balloon angioplasty was utilized as a predilating modality prior to DCA. The thrombolytic agent urokinase was utilized in five of these eight patients, either before, during, or after angioplasty and/or DCA.  DCA success (defined as ability to cross the lesion, reduction of less than or equal to 20% in stenosis and thrombolysis--when a thrombus is present) was achieved in 10 of 11 patients.  One patient had persistent abrupt reclosure of an LAD lesion, accompanied by hemodynamic compromise, necessitating intra-aortic balloon pump insertion and subsequent emergent coronary artery bypass graft surgery.  Final angiograms revealed residual stenoses less than or equal to 20%, and adequate thrombolysis.  Significant cardiac events were limited to one emergent CABG, Q wave MI in four patients, and non-Q wave MI in two patients.  Clinically all eleven patients improved, survived the AMI/CABG, and were discharged.  This clinical experience demonstrates the feasibility and safety of DCA application in selected patients who experience acute myocardial infarction.
Baldwin
T F
TF
Shawnee Mission Hospital, Kansas  66204.
Lash
R E
RE
Whitfield
S S
SS
Toalson
W B
WB
Murphy
J W
JW
Dreiling
R J
RJ
Hawkins
J
J
Hansell
H N
HN
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D017225:Atherectomy, Coronary / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000601:surgery*; D011183:Postoperative Complications; D012307:Risk Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use